ReviewCurrent allergy and asthma reports2014
Immune mechanisms of sublingual immunotherapy.
Review in Current allergy and asthma reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04813380 (Serum MicroRNAs 223 and 146a in Allergic Rhinitis Patients), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Serum MicroRNAs 223 and 146a in Allergic Rhinitis Patients: Correlation With Disease Severity and Their Role as Biomarkers for Efficacy of Sublingual Immunotherapy
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Article
- A novel oral immunotherapy strategy using transgenic barley inducesFrontiers in immunology · 2026Article
- The Relationship Between Asthma and Food Allergies in Children.Children (Basel, Switzerland) · 2024Review
- Cuproptosis-related gene DLAT is a biomarker of the prognosis and immune microenvironment of gastric cancer and affects the invasion and migration of cells.Cancer medicine · 2024Article
- Substance P promotes immunotherapy efficacy for airway allergy.The World Allergy Organization journal · 2023Article
- The clinical and immunological basis of early food introduction in food allergy prevention.Frontiers in allergy · 2023Review
- CpG-ODN Signaling via Dendritic Cells-Expressing MyD88, but Not IL-10, Inhibits Allergic Sensitization.Vaccines · 2021Article
- Sublingual immunotherapy for food allergy and its future directions.Immunotherapy · 2020Review
- Could This Be IT? Epicutaneous, Sublingual, and Subcutaneous Immunotherapy for the Treatment of Food Allergies.Current allergy and asthma reports · 2019Review
- Sublingual immunotherapy with recombinant Mal d 1 downregulates the allergen-specific Th2 response.Allergy · 2019Article
- Article
- Comparison of sublingual immunotherapy and oral immunotherapy in peanut allergy.Allergo journal international · 2018Article
- Allergen-Specific Immunotherapies for Food Allergy.Allergy, asthma & immunology research · 2018Review
- Current Status of Potential Therapies for IgE-Mediated Food Allergy.Current allergy and asthma reports · 2018Review
- Morphofunctional analysis of antigen uptake mechanisms following sublingual immunotherapy with beads in mice.PloS one · 2018Article
- Article
- Immunoglobulin Glycosylation Effects in Allergy and Immunity.Current allergy and asthma reports · 2016Review
- Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma.Current allergy and asthma reports · 2016Review
- Basic science for the clinician: Mechanisms of sublingual and subcutaneous immunotherapy.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2016Review
- Potential Involvement of Type I Interferon Signaling in Immunotherapy in Seasonal Allergic Rhinitis.Journal of immunology research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sublingual immunotherapy (SLIT) is a well-established allergen-specific immunotherapy and a safe and effective strategy to reorient inappropriate immune responses in allergic patients. SLIT takes advantage of the tolerogenic environment of the oral mucosa to promote tolerance to the allergen. Several clinical studies have investigated the complex interplay of innate and adaptive immune responses that SLIT exploits. The oral immune system is composed of tolerogenic dendritic cells that, following uptake of allergen during SLIT, support the differentiation of T helper cell type 1 (Th1) and the induction of IL-10-producing regulatory T cells. Following SLIT, allergic disease-promoting T helper cell type 2 (Th2) responses shift to a Th1 inflammatory response, and IL-10 and transforming growth factor (TGF)-β production by regulatory T cells and tolerogenic dendritic cells suppress allergen-specific T cell responses. These immune changes occur both in the sublingual mucosa and in the periphery of a patient following SLIT. SLIT also promotes the synthesis of allergen-specific IgG and IgA antibodies that block allergen-IgE complex formation and binding to inflammatory cells, thus encouraging an anti-inflammatory environment. Several of these revealing findings have also paved the way for the identification of biomarkers of the clinical efficacy of SLIT. This review presents the emerging elucidation of the immune mechanisms mediated by SLIT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.